AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active

$5.49

$-0.13(-2.32%)

Market Cap$1.7B

P/E Ratio—

52W High$6.79

52W Low$2.33

Avg Volume5.9M

Open$5.86

Beta1.18

Net Income Financials Revenue

AbCellera Biologics Inc. (ABCL) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ABCL · net income · updated Jun 8, 2026

Core profitability metrics

ABCL · net income · margin · TTM · CAGR

Net income was −$146.4M for FY2025 (fiscal year ending 2025-12-31), up 10.1% year-over-year. Net profit margin was -194.9%. Based on available data, AbCellera Biologics Inc. has been profitable since at least 2018.

FY2025 Net Income−$146.4M▲ +10.1% YoY

Trailing 12M (TTM)−$144.0Mtrailing 4 quarters sum

Net Profit Margin-194.9%−$146.4M ÷ $75.1M

YoY Change+10.1%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2018

▸ FMP /income-statement · Annual · ABCL net income history · ABCL profit margin

Annual net income data

ABCL · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$146.4M▲ +10.1%-194.9%$75.1M

FY2024Loss−$162.9M▼ 11.2%-564.8%$28.8M

FY2023Loss−$146.4M▼ 192.4%-385.0%$38.0M

FY2022$158.5M▲ +3.3%32.7%$485.4M

FY2021$153.5M▲ +29.1%40.9%$375.2M

Net income vs peers (Healthcare)

ABCL vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

AbCellera Biologics Inc.YOU

ABCL

−$146.4M+10.1%-194.9%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

AbCellera Biologics Inc. (ABCL) reported net income of −$146.4M for FY2025 (fiscal year ending 2025-12-31), up 10.1% year-over-year. The net profit margin was -194.9% — meaning the company kept $-1.95 of every dollar of revenue as profit.

Based on available data, AbCellera Biologics Inc. has been profitable since at least 2018. Net income reached a peak of $158.5M in FY2022. Data available for 8 fiscal years.

AbCellera Biologics Inc.'s net profit margin was -194.9% for FY2025, based on the latest annual results.

Investors sometimes search for "AbCellera Biologics Inc. net worth" — the company's market capitalization is a separate figure from ABCL net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ABCL net income · 4 questions

AbCellera Biologics Inc. is not currently profitable on an annual basis. The company reported a net loss of $146.4M for FY2025.

is ABCL profitabledoes ABCL make a profitABCL profitabilityABCL profitable company

▸ Source: FMP /income-statement · GAAP · AbCellera Biologics Inc. · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026